Imago BioSciences

IMGO

This biopharmaceutical company develops small molecule therapies targeting epigenetic enzymes to treat patients with bone marrow diseases and chronic blood cancers.

Ajax Therapeutics

This biopharmaceutical company develops next-generation JAK2 inhibitors to treat patients with myeloproliferative neoplasms, a group of rare chronic blood cancers.

Imara

This biopharmaceutical company develops oral small-molecule therapies to treat patients with rare genetic blood disorders, including sickle cell disease and beta thalassemia.

Damora Therapeutics

This biotechnology company develops subcutaneous biologics to treat patients with mutant calreticulin-driven myeloproliferative neoplasms and other chronic blood disorders.

TargeGen

This company develops small molecule kinase inhibitors to treat blood disorders and inflammatory diseases for patients with unmet medical needs.

Endeavor BioMedicines

This clinical-stage biotechnology company develops small-molecule inhibitors and therapies for patients with oncology and fibrotic lung diseases.

Kronos Bio

This biopharmaceutical company develops small molecule therapeutics targeting transcription factors for patients with cancer and autoimmune diseases.

Constellation Pharmaceuticals

This biopharmaceutical company develops small-molecule epigenetics therapies to treat patients with blood cancers and solid tumours.